Aquestive Secures $150M Debt Refinancing with Oaktree for Anaphylm Launch
Event summary
- Aquestive refinanced $150M debt with Oaktree, replacing $45M existing loan.
- $55M drawn at closing; additional $20M upon FDA approval of Anaphylm.
- $25M tied to sales milestones, $50M contingent on mutual consent.
- Reduces principal debt repayments to zero for next three years.
- Interest-only payments over five-year term; principal due at maturity.
The big picture
Aquestive's $150M refinancing with Oaktree underscores confidence in Anaphylm's regulatory and commercial prospects. The deal reduces near-term debt pressure while aligning capital deployment with product milestones—a common strategy for pre-revenue biotechs navigating FDA approvals. Oaktree's $6B life sciences lending track record suggests this transaction reflects both Aquestive's specific needs and broader industry trends toward flexible, milestone-based financing.
What we're watching
- Regulatory Timing
- Whether Anaphylm secures FDA approval and triggers $20M funding.
- Commercial Execution
- The pace at which Anaphylm achieves sales milestones to unlock $25M tranche.
- Capital Flexibility
- How Aquestive deploys the refinancing proceeds beyond Anaphylm launch.
Related topics